
09/03/2025
Proud to celebrate a major milestone with Neucore Bio!
They’ve been awarded a new NIH (The National Institutes of Health) National Center for Advancing Translational Sciences (NCATS) STTR Phase I grant to advance their FiXE™ exosome platform, a promising non-viral delivery system for genetic medicines targeting Schwann cells. This breakthrough approach could open the door to new treatments for neuromuscular disorders like Charcot-Marie-Tooth disease.
We’re proud to support Neucore Bio and their brilliant scientific co-founders, Daniel Gallego-Perez and Natalia Higuita-Castro, at The Ohio State University Gene Therapy Institute as they push the boundaries of what’s possible in genetic medicine.
🔗 Read more here: https://neucorebio.com/neucore-bio-awarded-nih-sttr-phase-i-grant-to-pursue-exosome-based-genetic-medicine-for-charcot-marie-tooth-disease-type-1a-cmt1a/